Through continuous R&D, GeneMatrix will become
a company specializing in vaccine development.

Hepatitis A vaccine (GMAI-02)

Hepatitis A vaccine has been included in the National Essential Immunizations (NIP) list since 2015, but there are no domestically developed products to date, so the country relies entirely on imports. In order to localize the hepatitis A vaccine, our company began the development of a hepatitis A killed vaccine. Recognized for the effectiveness of the vaccine candidate using the hepatitis A virus strain we developed ourselves, we won an order for the vaccine commercialization technology development project from the Ministry of Health and Welfare in 2020 and received an order from Kyung Hee University. We jointly developed a highly effective domestically produced vaccine with the school. In addition, in 2021, we won an order for the infectious disease prevention and treatment technology development project from the same ministry and developed a hepatitis A vaccine efficacy evaluation method together with the Jeonnam Bio Industry Promotion Agency's Biopharmaceutical Research Center and Vaccine Safety Technology Support Center. In 2022, we won an order for the Ministry of Health and Welfare's vaccine commercialization technology development project and are conducting research and development to enter clinical trials for the hepatitis A vaccine.

Japanese encephalitis inactivated vaccine (GMJI-01)

Although the Japanese encephalitis vaccine is currently included in the National Essential Immunizations (NIP) items in Korea, the four types of domestically distributed vaccines are all manufactured domestically by importing the crude solution or importing the finished product, so domestic production is urgently needed. Our research team has begun the domestic production of a Japanese encephalitis vaccine in 2021, taking advantage of our experience in developing Japanese encephalitis vaccine candidates, licensing them out to global pharmaceutical companies, and commercializing them. Afterwards, in recognition of the potential of the vaccine candidate material, we received an order for a vaccine commercialization technology development project from the Ministry of Health and Welfare in 2022, and are currently developing the vaccine for localization.

Herpes zoster (GM-ChimAd-VZ)

Currently, attenuated virus vaccines and recombinant protein vaccines dominate the herpes zoster market, and GeneMatrix is developing an effective herpes zoster using the chimeric adenovirus vector platform, a proven source technology in the COVID-19 vaccine development process.

HPV therapeutic vaccine (GM-ChimAd-PV)

Cervical cancer is the fourth most common cancer in women, and the number of patients diagnosed with cervical cancer worldwide reaches 570,000 every year, with an average of 853 deaths per day. Human papillomavirus (HPV) is the main cause of cervical cancer, and in particular, high-risk HPV types 16 and 18 are known to cause more than 70% of cervical cancer. However, because there is currently no commercialized HPV therapeutic vaccine, extensive research and clinical trials are underway on various types of vaccine candidates. As an HPV therapeutic vaccine, our company is developing an effective therapeutic vaccine using AI-based proprietary antigen remodeling technology and T cell immunity-promoting protein fusion technology. ‘GMPV-12’ is a mechanism that treats cancer by activating T immune cells, and its effectiveness was confirmed using a cervical cancer animal model.

Zika virus vaccine

Zika virus infection is a mosquito-borne infection, and global health-related organizations such as WHO and CDC are investing large budgets to control, treat, and prevent it. However, new characteristics, such as the possibility of sexually transmitted infection and tropism for nervous system cells, which were previously unknown in the same family of viruses, are being revealed, and as there is no clear treatment to date, the importance of rapid vaccine development as the only alternative to prevent infection is increasing. It's getting bigger. In 2021, our company developed a mutant Zika virus strain and applied for a patent, completed the development of a killed vaccine (GMZ-002) production process using it, and demonstrated excellent protective effects against infection in animal models. In addition, we developed a Zika virus recombinant vaccine candidate (GMZV-01) together with the Korea Disease Control and Prevention Agency and established a vaccine purification and efficacy evaluation system.

COVID-19 vaccine (GM-ChimAd-CV)

In order to respond to the global epidemic of the novel coronavirus SARS-CoV-2, our company is developing a novel coronavirus vaccine using the chimeric adenovirus vector platform source technology. As a result of developing four types of candidate substances and conducting an efficacy evaluation in collaboration with the International Vaccine Institute (IVI), an internationally recognized organization, excellent cross-protection effects were confirmed against mutant virus strains, including delta mutant strains. Our company was recognized for the excellence of ‘GM-ChimAd-CV’, a COVID-19 vaccine candidate, and won an order for a non-clinical support project from the New Drug Development Business Group, successfully completing non-clinical testing. We plan to proceed with rapid clinical development in the future to secure a domestically produced novel coronavirus vaccine that urgently needs society.